Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients

Research output: Contribution to journalArticlepeer-review

Abstract

Hydroxychloroquine is used extensively in the treatment of systemic lupus erythematosus, not only for its benefit for cutaneous and musculoskeletal lupus, but also for its role in preventing flares, preventing renal and central nervous system lupus, and improving survival rates. Hydroxychloroquine also has known benefits in reducing some traditional cardiovascular risk factors, such as hyperlipidemia and diabetes mellitus. This article reviews its possible role as an antithrombotic drug in the general population, in systemic lupus erythematosus, and in patients with antiphospholipid antibodies.

Original languageEnglish (US)
Pages (from-to)77-80
Number of pages4
JournalCurrent rheumatology reports
Volume13
Issue number1
DOIs
StatePublished - Feb 2011

Keywords

  • Antiphospholipid antibodies
  • Hydroxychloroquine

ASJC Scopus subject areas

  • Rheumatology

Fingerprint Dive into the research topics of 'Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients'. Together they form a unique fingerprint.

Cite this